Cellosaurus 451Lu (CVCL_6357)

Cell line name 451Lu
Synonyms 451LU; 451-LU; WM 451-Lu; WM-451Lu; WM-451LU; WM451Lu; WM451; WC00059; LU451; EST81
Accession CVCL_6357
Resource Identification Initiative To cite this cell line use: 451Lu (RRID:CVCL_6357)
Comments Part of: Wistar Institute melanoma cell line collection.
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: Heterozygous for BRAF p.Val600Glu (Wistar).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Transcriptome analysis.
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_7928 (WM164)
Children: CVCL_AP83 (451Lu-BR); CVCL_DG54 (451Lu-MR)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ESTDAB; Wistar

Markers:
AmelogeninX
CSF1PO12 (ATCC; Cosmic-CLP; ESTDAB)
11,12 (Wistar)
D13S31711
D16S53913
D18S5110
D19S43313
D21S1128,31.2
D2S133818,19
D3S135818
D5S81812 (ATCC; Cosmic-CLP; ESTDAB)
11,12 (Wistar)
D7S8209,10 (ATCC; ESTDAB; Wistar)
10 (Cosmic-CLP)
D8S117913,14
FGA21,25 (ESTDAB)
21 (Wistar)
TH019
TPOX8,10
vWA14,15
Web pages http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-0
http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-metastatic-melanoma-cell-lines-the-primary-lesi
http://www.rockland-inc.com/Product.aspx?id=51606
Publications

PubMed=2918552; DOI=10.1093/jnci/81.6.440
Iliopoulos D., Ernst C., Steplewski Z., Jambrosic J.A., Rodeck U., Herlyn M., Clark W.H. Jr., Koprowski H., Herlyn D.
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.
J. Natl. Cancer Inst. 81:440-444(1989)

PubMed=2156614
Herlyn D., Iliopoulos D., Jensen P.J., Parmiter A., Baird J., Hotta H., Adachi K., Ross A.H., Jambrosic J.A., Koprowski H., Herlyn M.
In vitro properties of human melanoma cells metastatic in nude mice.
Cancer Res. 50:2296-2302(1990)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

PubMed=8342600
Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K., Herlyn D., Valyi-Nagy I.T., Herlyn M.
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice.
Am. J. Pathol. 143:528-537(1993)

PubMed=17260012; DOI=10.1038/sj.onc.1210252
Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M., Guldberg P., Borg A.
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene 26:4738-4748(2007)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023
Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M., Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A., Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K., DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C., Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X., Schuchter L.M., Herlyn M., Nathanson K.L.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep. 4:1090-1099(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; CRL-2813 - Discontinued
Coriell; WC00059 - Discontinued
Cell line databases/resources Cosmic-CLP; 1287706
ESTDAB; ESTDAB-081
GDSC; 1287706
Ontologies BTO; BTO:0003710
CLO; CLO_0001373
Biological sample resources BioSample; SAMN03471798
Gene expression databases GEO; GSM156019
GEO; GSM188238
GEO; GSM188268
GEO; GSM188327
GEO; GSM555187
GEO; GSM952579
GEO; GSM1199178
GEO; GSM1669568
Polymorphism and mutation databases Cosmic; 686411
Cosmic; 1047656
Cosmic; 1155281
Cosmic; 1155568
Cosmic; 1187587
Cosmic; 1303027
Cosmic; 2163808
Cosmic; 2230114